NAMS · Company research
NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
16records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| NewAmsterdam Pharma Company N.V. (NAMS) stock price, news, quote and history - Yahoo Finance Australia | NewAmsterdam Pharma Company N.V. (NAMS) stock price, news, quote and history Yahoo Finance Australia | View source ↗ | Yahoo Finance Australia | Oct 14, 2026 | neutral | 0 | 0.6 |
| SPINOZA Trial Start Could Be A Game Changer For NewAmsterdam Pharma Stock (NAMS) - Simply Wall Street | SPINOZA Trial Start Could Be A Game Changer For NewAmsterdam Pharma Stock (NAMS) Simply Wall Street | View source ↗ | Simply Wall Street | Oct 10, 2026 | neutral | 0 | 0.6 |
| After exercising options, Futurum sold 50,246 NewAmsterdam Pharma (NAMS) shares at an average $25.03. - Stock Titan | After exercising options, Futurum sold 50,246 NewAmsterdam Pharma (NAMS) shares at an average $25.03. Stock Titan | View source ↗ | Stock Titan | Oct 2, 2026 | neutral | 0 | 0.6 |
| Seven new hires receive stock options to buy NewAmsterdam shares at $24.16 each. - Stock Titan | Seven new hires receive stock options to buy NewAmsterdam shares at $24.16 each. Stock Titan | View source ↗ | Stock Titan | Oct 2, 2026 | neutral | 0 | 0.6 |
| A drug trial will study about 400 people with Alzheimer’s-related changes but no noticeable symptoms. - Stock Titan | A drug trial will study about 400 people with Alzheimer’s-related changes but no noticeable symptoms. Stock Titan | View source ↗ | Stock Titan | Sep 29, 2026 | neutral | 0 | 0.6 |
| Five Frazier funds detail their NewAmsterdam (NASDAQ: NAMS) positions - Stock Titan | Five Frazier funds detail their NewAmsterdam (NASDAQ: NAMS) positions Stock Titan | View source ↗ | Stock Titan | Sep 22, 2026 | neutral | 0 | 0.6 |
| NewAmsterdam Pharma (NasdaqGM:NAMS) Stock Forecast & Analyst Predictions - Simply Wall Street | NewAmsterdam Pharma (NasdaqGM:NAMS) Stock Forecast & Analyst Predictions Simply Wall Street | View source ↗ | Simply Wall Street | Sep 21, 2026 | neutral | 0 | 0.6 |
| NewAmsterdam Pharma (NAMS) Stock Looks Above Fair Value After Its 139% Run - Yahoo Finance | NewAmsterdam Pharma (NAMS) Stock Looks Above Fair Value After Its 139% Run Yahoo Finance | View source ↗ | Yahoo Finance | Sep 19, 2026 | neutral | 0 | 0.6 |
| $NAMS stock is down 10% today. Here's what we see in our data. - Quiver Quantitative | $NAMS stock is down 10% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Sep 9, 2026 | neutral | 0 | 0.6 |
| $NAMS stock is down 10% today. Here's what we see in our data. - Quiver Quantitative | $NAMS stock is down 10% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Sep 9, 2026 | neutral | 0 | 0.6 |
| NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance | NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Lags Revenue Estimates Yahoo Finance | View source ↗ | Yahoo Finance | Aug 5, 2026 | neutral | 0 | 0.6 |
| NewAmsterdam Pharma: Obicetrapib Is More Than Another LDL-Lowering Pill - Seeking Alpha | NewAmsterdam Pharma: Obicetrapib Is More Than Another LDL-Lowering Pill Seeking Alpha | View source ↗ | Seeking Alpha | Jul 25, 2026 | neutral | 0 | 0.6 |
| NewAmsterdam Pharma(NAMS.US) Officer Sells US$3.19 Million in Common Stock - Moomoo | NewAmsterdam Pharma(NAMS.US) Officer Sells US$3.19 Million in Common Stock Moomoo | View source ↗ | Moomoo | Jul 22, 2026 | neutral | 0 | 0.6 |
| Industry Analysts Just Made A Substantial Upgrade To Their NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Revenue Forecasts - Simply Wall Street | Industry Analysts Just Made A Substantial Upgrade To Their NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Revenue Forecasts Simply Wall Street | View source ↗ | Simply Wall Street | May 13, 2026 | neutral | 0 | 0.6 |
| Do NewAmsterdam Pharma’s (NAMS) Dilution Plans Reframe Its Path to Funding Ongoing Losses? - Yahoo Finance | Do NewAmsterdam Pharma’s (NAMS) Dilution Plans Reframe Its Path to Funding Ongoing Losses? Yahoo Finance | View source ↗ | Yahoo Finance | May 8, 2026 | neutral | 0 | 0.6 |
| NAMS Stock Price and Chart — NASDAQ:NAMS - TradingView | NAMS Stock Price and Chart — NASDAQ:NAMS TradingView | View source ↗ | TradingView | Feb 25, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.